For a therapeutic molecule to work, it must not only reach its target but also fit precisely within a specific binding pocket. Drug resistance often arises when a single genetic mutation alters the geometry or flexibility of this pocket. Rather than simply "breaking" the protein, these mutations create structural interference—physical or conformational barriers that selectively exclude the drug while often allowing the protein to continue its biological function.
Physical Exclusion through Steric Hindrance
The most direct form of structural interference is steric hindrance, where a mutation replaces a small amino acid with a bulkier one. This change acts as a physical roadblock at the entrance or within the heart of a binding pocket.
As Oltvai et al. demonstrate in the context of acute myeloid leukemia, a secondary mutation in the IDH1 protein (p.S280F) introduces a bulky phenylalanine side chain that physically blocks the inhibitor ivosidenib from entering its target site. Similarly, Li et al. explain that "gatekeeper" mutations in tyrosine kinases often substitute small residues for larger ones. Crucially, this modification can be highly selective: the bulky residue creates a steric clash with the synthetic drug but is positioned such that the protein’s natural, smaller substrate (like ATP) can still bind, allowing the disease-driving protein to remain active.
This principle extends to larger biological structures as well. In Staphylococcus aureus, the authors of a 2018 study found that a 27-nucleotide insertion in the rplV gene extends the protein loops lining the ribosomal exit tunnel. This structural modification narrows the tunnel just enough to prevent macrolide antibiotics from binding, without halting the ribosome's primary task of protein synthesis.
Disrupting the Induced Fit
Binding is rarely a static "lock and key" mechanism; it often requires the protein to change shape to "envelop" the drug, a process known as induced fit. Structural interference can occur by rigidifying the protein, preventing this necessary movement.
Sun et al. explored this in the ROS1 kinase, where the G2032R mutation makes the protein's "P-loop" too rigid to close around the drug crizotinib. By stabilizing the loop in an "open" conformation, the mutation removes the energy barriers required to trap the drug, causing it to dissociate too quickly to be effective.
A similar mechanism of "conformational locking" is seen in viral evolution. Viswanathan et al. identified that specific mutations in influenza hemagglutinin can create internal hydrogen bonds. these bonds lock the protein into a rigid, non-functional state that prevents it from binding to receptors, effectively creating an evolutionary dead-end by interfering with the protein's required flexibility.
Mapping the Geometry of Resistance
To combat these structural barriers, researchers are moving toward predictive geometric modeling. Traditional methods often focus on binding free energy, but these can miss the physical "why" of resistance.
Ma and Zou developed an "alpha shape" model to analyze the surface curvature and "knob levels" of binding pockets in mutated EGFR proteins. By identifying the exact physical coordinates of an obstruction, researchers can design smaller or more flexible chemical fragments that bypass these specific barriers, a strategy Munir et al. suggest is vital for creating "resistance-proof" antibiotics for tuberculosis.
Furthermore, the structural consequences of a mutation are not always localized to the binding site itself. Vedithi et al. and Zou et al. argue that initial mutations can destabilize the overall protein scaffold, making the structure more susceptible to acquiring further resistance-inducing changes. Understanding these dynamic vulnerabilities allows for the design of therapeutics, such as the minibinders developed by Weng et al., that target conserved regions less prone to structural interference.
Key Foundational Work
P-loop Conformation Governed Crizotinib Resistance in G2032R-Mutated ROS1 Tyrosine Kinase: Clues from Free Energy Landscape (2014) — contributed 2 concept elements to this direction.
Determinants of Glycan Receptor Specificity of H2N2 Influenza A Virus Hemagglutinin (2010) — contributed 2 concept elements to this direction.